Bifunctional molecules that induce targeted degradation and transcytosis of extracellular proteins in brain cells

21 August 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

We present the application of Angiopep-2 as a molecular degrader of extracellular proteins (MoDE) promoting target protein removal by both transcytosis and lysosomal degradation mechanisms in brain endothelial cells. The accumulation of pathogenic proteins is a hallmark of many neurodegenerative diseases, and removal of these species is a promising avenue for the development of novel therapies. Targeted protein degradation technologies are emerging as efficacious therapeutic strategies in a wide range of diseases. However, there are no existing methods for the degradation of extracellular proteins in the central nervous system (CNS). Angiopep-2, a brain-targeting peptide derived from aprotinin, has previously been employed as a covalent tag to facilitate receptor-mediated transcytosis of therapeutics across the blood brain barrier (BBB). MoDEs/LyTACs consisting of Angiopep-2 modified with biotin or a chloroalkane ligand triggered endocytosis of streptavidin and HaloTag protein, respectively. Interestingly, uptake occurred independently of LRP-1, which is the reported receptor for Angiopep-2. MoDE-mediated endocytosis of streptavidin in a bEnd.3 BBB model resulted in two mechanisms of protein removal: both bi-directional transcytosis and lysosomal degradation. This study demonstrates that Angiopep-2-based MoDEs can recruit, endocytose, and degrade proteins of interest in CNS cells, supporting their further development as molecular degraders of pathogenic neuroproteins.

Keywords

MoDE
LYTAC
Angiopep-2
Targeted Protein Degradation

Supplementary materials

Title
Description
Actions
Title
Supplementary Data
Description
Supplementary Figures and Chemical Characterization
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.